Hanna Krauss

Prof. Dr. Hanna Krauss


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
KMKlaudiusz Mankiewicz
Klaudiusz Mankiewicz
MWMikołaj Wachowski
Mikołaj Wachowski
JKJulia Kłos
Julia Kłos
SKStanisław Klamecki-Cichy
Stanisław Klamecki-Cichy
HKHanna Krauss
Hanna Krauss
Background: Favorable attitudes toward human papillomavirus (HPV) vaccination do not necessarily translate into vaccine uptake, particularly among young adults who were too old to benefit from recently expanded adolescent programs. We assessed the gap between attitudes and self-reported HPV vaccination and examined sociodemographic and psychosocial correlates of uptake in a non-probability sample of young adults residing in Poland. Methods: An anonymous cross-sectional online survey was conducted from 12 January 2025 to 14 August 2026. The analysis included 334 complete responses from adults aged 18–45 years recruited through social media. The 42-item questionnaire assessed sociodemographic characteristics, HPV knowledge, vaccine trust, perceived personal threat, social exposure to vaccinated persons, access, and barriers. Group differences were examined using Pearson chi-square tests. Multivariable logistic regression estimated adjusted odds ratios (aORs) for self-reported vaccination; two respondents reporting sex as other/prefer not to say were excluded from the sex-adjusted model (N=332). Results: Overall, 113/334 participants (33.8%) reported HPV vaccination, whereas 300/334 (89.8%) considered vaccination important. Among unvaccinated respondents, the most frequent barriers were lack of a clinician recommendation (83/221; 37.6%) and cost (75/221; 33.9%). In the adjusted model, vaccination was associated with female sex (aOR 2.49, 95% CI 1.10–5.65), greater vaccine trust (aOR 1.70 per scale point, 95% CI 1.17–2.45), and knowing a vaccinated person (aOR 7.73, 95% CI 4.02–14.86). Compared with participants aged 25 years (aOR 0.27, 95% CI 0.09–0.86) had lower odds of vaccination. Objective HPV knowledge, education, urban residence, region, and medical/health-related study or work were not independently associated with uptake in this exploratory model. Model AUC was 0.846. Conclusions: In this non-probability sample, the gap between endorsing HPV vaccination as important and self-reported uptake was substantial; this construct should not be interpreted as an intention–behavior gap. Vaccine confidence and reported social exposure showed stronger cross-sectional associations with HPV vaccination than the exploratory objective-knowledge score, while lack of clinician recommendation and cost remained prominent barriers. These findings support evaluation of catch-up strategies that combine clear clinician recommendation, affordable and convenient access, gender-neutral cancer-prevention communication, and social normalization of vaccination.

18 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
DKDariusz Kowalczyk
Dariusz Kowalczyk
JJJolanta Jaworek
Jolanta Jaworek
ACAndrzej Adam Ciborek
Andrzej Adam Ciborek
Paweł KołodziejskiPaweł Kołodziejski
Paweł Kołodziejski
EPEwa Pruszynska-Oszmalek
Ewa Pruszynska-Oszmalek
HKHanna Krauss
Hanna Krauss
Background: The therapeutic management of cutaneous malignancies—cutaneous melanoma, cutaneous squamous-cell carcinoma (cSCC), basal-cell carcinoma (BCC) and Merkel-cell carcinoma (MCC)—has shifted toward multimodal, stage-adapted treatment integrating surgery, radiotherapy, molecularly targeted therapy and immune checkpoint inhibition. Methods: We conducted a structured narrative review with a structured literature search of PubMed/MEDLINE, Scopus and Web of Science (January 2015–6 September 2026), prioritising current clinical practice guidelines, randomised controlled trials and phase II–III studies; landmark older trials were included separately. Synthesis: Surgery with adequate histological margins, including Mohs micrographic surgery where appropriate, remains definitive for localised disease. In resectable macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab with response-driven postoperative management improved event-free survival versus adjuvant nivolumab in NADINA. SWOG S1801 independently demonstrated an event-free-survival advantage for perioperative pembrolizumab over adjuvant-only pembrolizumab in resectable stage III–IV melanoma. In advanced melanoma, dual immune-checkpoint strategies and BRAF/MEK inhibition require patient-specific sequencing; in the European Union, nivolumab plus relatlimab is authorised for first-line advanced melanoma with tumour-cell PD-L1 expression <1%. In high-risk cSCC after surgery and radiotherapy, adjuvant cemiplimab improved disease-free survival. In advanced BCC, Hedgehog-pathway inhibitors remain the principal first systemic option, with anti-PD-1 therapy after HHI failure or intolerance. Clinical implications: Molecular testing should be indication-driven: BRAF V600 is a validated treatment-selecting biomarker, while broader NGS profiling (including NRAS, KIT, NF1, TERT and co-occurring alterations), PD-L1, tumour mutational burden and circulating tumour DNA have context-dependent, supportive or investigational roles. Conclusions: The major unresolved issues are optimal sequencing, response-adapted perioperative treatment, resistance, biomarker validation and treatment of transplant, frail and other under-represented populations.

31 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KMKlaudiusz Mankiewicz
Klaudiusz Mankiewicz
MWMikołaj Wachowski
Mikołaj Wachowski
JKJulia Kłos
Julia Kłos
SKStanisław Klamecki-Cichy
Stanisław Klamecki-Cichy
HKHanna Krauss
Hanna Krauss
Background: Favorable attitudes toward human papillomavirus (HPV) vaccination do not necessarily translate into vaccine uptake, particularly among young adults who were too old to benefit from recently expanded adolescent programs. We assessed the gap between attitudes and self-reported HPV vaccination and examined sociodemographic and psychosocial correlates of uptake among young adults in Poland. Methods: An anonymous cross-sectional online survey was conducted from 12 January 2025 to 14 August 2026. The analysis included 334 complete responses from adults aged 18–45 years recruited through social media. The 42-item questionnaire assessed sociodemographic characteristics, HPV knowledge, vaccine trust, perceived personal threat, social exposure to vaccinated persons, access, and barriers. Group differences were examined using Pearson chi-square tests. Multivariable logistic regression estimated adjusted odds ratios (aORs) for self-reported vaccination; two respondents reporting sex as other/prefer not to say were excluded from the sex-adjusted model (N=332). Results: Overall, 113/334 participants (33.8%) reported HPV vaccination, whereas 300/334 (89.8%) considered vaccination important. Among unvaccinated respondents, the most frequent barriers were lack of a clinician recommendation (83/221; 37.6%) and cost (75/221; 33.9%). In the adjusted model, vaccination was associated with female sex (aOR 2.49, 95% CI 1.10–5.65), greater vaccine trust (aOR 1.70 per scale point, 95% CI 1.17–2.45), and knowing a vaccinated person (aOR 7.73, 95% CI 4.02–14.86). Compared with participants aged < 20 years, those aged 23–25 years (aOR 0.33, 95% CI 0.12–0.86) and >25 years (aOR 0.27, 95% CI 0.09–0.86) had lower odds of vaccination. Objective HPV knowledge, education, urban residence, region, and medical/health-related study or work were not independently associated with uptake. Model AUC was 0.846. Conclusions: In this non-probability sample, the attitude-uptake gap was substantial. Vaccine confidence and social exposure were more strongly associated with HPV vaccination than objective knowledge, while lack of clinician recommendation and cost remained prominent barriers. Catch-up strategies for young adults should combine clear clinician recommendation, affordable and convenient access, gender-neutral cancer-prevention communication, and social normalization of vaccination.